Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
My previous session
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Ablynx : posts strong data on key drug, looks set for approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 10:40am CEST

The drug, caplacizumab, is a treatment for the rare condition acquired thrombotic thrombocytopenic purpura (aTTP) and the data revealed a 74% reduction in aTTP-related death, recurrence of aTTP or at least one major thromboembolic event during treatment with its drug.

Additionally, the proportion of individuals that experienced recurrence of aTTP during the study was found 67% lower compared to those receiving placebo treatment.

In a further bonus to the drug, the safety profile was found to be extremely strong, with no major differences found between the drug and placebo treatment. The exception being a higher level of bleed-related adverse events, 66.2% against 49.3% in placebo though they were noted to be mild or moderate in severity.

Dr Edwin Moses, CEO of Ablynx, commented: I am delighted by this outcome as it reinforces all our beliefs in the potential for caplacizumab to change the lives of patients affected by aTTP. This is a very important milestone for the company as it further validates our Nanobody platform and demonstrates our ability to discover and develop medicines that make a real difference for society. These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available.

Ablynx has already applied for marketing authorisation the EMA and plans to file with the FDA in 2018. One of the major successes for the company is that the Belgium-based biotech has taken the treatment all the way through to Phase 3 by itself and now looks set to secure the potential peak sales of $400 million exclusively. It has already announced that it plans to market the drug with its own sales force.

European biotechs have, so far, lagged behind their counterparts across the Atlantic but this success will go some way to suggesting that it is possible within Europe to develop a company able to take treatments all the way through developmental stage to potential marketing authorisation.

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
09/05SANOFI : reaps first fruit of Ablynx buyout with a European OK for its lead rare..
AQ
09/04SANOFI : 's Cablivi gains EU approval, Priority Review in U.S.
AQ
07/10ACCELERON PHARMA : Appoints Robert K. Zeldin, M.D., Chief Medical Officer
AQ
07/06SANOFI : - CHMP recommends approval of Cablivi
AQ
06/30Sanofi, Advent finally shake hands on $2.2B European generics sale
AQ
06/29ABLYNX : `Rapidly evolving` biotech company to create 10 jobs at York Science Pa..
AQ
06/29SANOFI : CHMP Recommends Approval of Cablivi (Caplacizumab)
AQ
06/22SANOFI : completes its acquisition of Ablynx following the expiration of the Squ..
AQ
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
More news
News from SeekingAlpha
05/02YOUR DAILY PHARMA SCOOP : KPTI Data, Allergan Write-Off, Celgene Down On Delay 
04/30Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV 
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
Financials (€)
Sales 2018 94,0 M
EBIT 2018 -9,76 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 37,2x
Capi. / Sales 2019 19,8x
Capitalization 3 498 M
Income Statement Evolution
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert Freisen Chief Scientific Officer
Remi Vermeiren Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX117.28%0
CELLTRION, INC.--.--%34 265
IQVIA HOLDINGS INC27.92%25 370
LONZA GROUP21.88%24 695
INCYTE CORPORATION-28.39%14 296
SEATTLE GENETICS, INC.45.25%12 306